Gene · 1441
CSF3R: colony stimulating factor 3 receptor
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CSF3R: colony stimulating factor 3 receptor. Genes, record 1441. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1441
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q99062 | Granulocyte colony-stimulating factor receptor | 836 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents123
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4739706 A1 | 2026-05-13 | 16 | Q99062 | Espacenet |
| EP 4727571 A2 | 2026-04-22 | 105 | Q99062 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 41935 | Q99062 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 41938 | Q99062 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 41939 | Q99062 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 8063 | Q99062 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 8174 | Q99062 | Espacenet |
| EP 4633648 A1 | 2025-10-22 | 36 | Q99062 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 16656 | Q99062 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 16721 | Q99062 | Espacenet |
1 to 10 of 123
See all 123 patentsDrugs10
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ANUMIGILIMAB | CHEMBL4650461 | Granulocyte colony stimulating factor receptor antagonist | ANTAGONIST | ChEMBL |
| BALUGRASTIM | CHEMBL2108572 | Granulocyte colony stimulating factor receptor agonist | AGONIST | ChEMBL |
| EFBEMALENOGRASTIM ALFA | CHEMBL4297950 | Granulocyte colony stimulating factor receptor agonist | AGONIST | ChEMBL |
| EFLAPEGRASTIM | CHEMBL3833384 | Granulocyte colony stimulating factor receptor agonist | AGONIST | ChEMBL |
| FILGRASTIM | CHEMBL1201567 | Granulocyte colony stimulating factor receptor agonist | AGONIST | ChEMBL |
| LENOGRASTIM | CHEMBL2109128 | Granulocyte colony stimulating factor receptor agonist | AGONIST | ChEMBL |
| LIPEGFILGRASTIM | CHEMBL4594230 | Granulocyte colony stimulating factor receptor agonist | AGONIST | ChEMBL |
| PEGFILGRASTIM | CHEMBL1201568 | Granulocyte colony stimulating factor receptor agonist | AGONIST | ChEMBL |
| PEGTEOGRASTIM | CHEMBL4297800 | Granulocyte colony stimulating factor receptor agonist | AGONIST | ChEMBL |
| REGRAMOSTIM | CHEMBL2107881 | Granulocyte colony stimulating factor receptor agonist | AGONIST | ChEMBL |
Trials1,643
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604233 | FILGRASTIM | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07585136 | FILGRASTIM | PHASE1 | ClinicalTrials.gov | |
| NCT07541755 | FILGRASTIM | PHASE3 | ClinicalTrials.gov | |
| NCT07541755 | PEGFILGRASTIM | PHASE3 | ClinicalTrials.gov | |
| NCT07541755 | LENOGRASTIM | PHASE3 | ClinicalTrials.gov | |
| NCT07537400 | REGRAMOSTIM | PHASE2 | ClinicalTrials.gov | |
| NCT07514936 | FILGRASTIM | PHASE3 | ClinicalTrials.gov | |
| NCT07514936 | PEGFILGRASTIM | PHASE3 | ClinicalTrials.gov | |
| NCT07514936 | LENOGRASTIM | PHASE3 | ClinicalTrials.gov | |
| NCT07514832 | FILGRASTIM | PHASE2 | ClinicalTrials.gov |
1 to 10 of 1,643
See all 1,643 trialsNIH grants1,645
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CSF3R papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 17 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 15 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 10 | 2025 |
| U54CA224019 | Architecture and Trajectory of Acquired Resistance to Therapy in AML | 9 | 2025 |
| P01CA066996 | Development of Novel Therapeutic Strategies in Human Leukemias | 7 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 7 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 6 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 5 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 5 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 5 | 2025 |
1 to 10 of 1,645Source NIH's project files
See all 1,645 nih grantsPapers3,351
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CIDER: detecting changes in gene regulatory networks that are associated with changes in phenotype. | bioRxiv | 2026 | 42818338 | PubTator, text mining | PubMed |
| CSF3R compound mutations produce a hyperproliferative leukemia driven by overexpression of PIM kinases. | Blood | 2026 | 42814612 | PubTator, text mining | PubMed |
| Serum NGAL and G-CSFR as Predictive and Prognostic Biomarkers for Trastuzumab-Based Therapy in HER2-Positive Gastric Cancer: A Retrospective Study. | Cancer Manag Res | 2026 | 42751472 | PubTator, text mining | PubMed |
| HIF1A+CSF3R+ neutrophils-dominated hypoxic niche induced metabolic reprogramming for neoadjuvant therapy resistance in NSCLC. | J Immunother Cancer | 2026 | 42711068 | PubTator, text mining | PubMed |
| Myeloid/Lymphoid Neoplasm with FGFR1::ZMYM2 Rearrangement Presenting as T-Cell Acute Lymphoblastic Lymphoma with Concurrent Myeloproliferative Neoplasm: A Case Report. | Hematol Rep | 2026 | 42645795 | PubTator, text mining | PubMed |
| Chronic Neutrophilic Leukemia in a Patient With Multiple Myeloma. | Cureus | 2026 | 42634708 | PubTator, text mining | PubMed |
| Enhanced prognosis of acute myeloid leukaemia patients with dmCEBPAbZIP -inf mutations: Insights from a multicentre Chinese cohort study. | Br J Haematol | 2026 | 42629624 | PubTator, text mining | PubMed |
| Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3-ITD-Positive AML. | Cancer Sci | 2026 | 42584468 | PubTator, text mining | PubMed |
| Longitudinal Molecular Characterization of a Rare TPM3::PDGFRB-Rearranged Myeloid/Lymphoid Neoplasm With Late CNL-Like Neutrophilic Evolution. | Eur J Haematol | 2026 | 42549531 | PubTator, text mining | PubMed |
| CCAAT/enhancer-binding protein alpha basic leucine zipper in-frame insertion/deletion (CEBPA bZIP-InDel-inf) defines a favourable-prognosis subgroup in CEBPA-mutated acute myeloid leukaemia. | Br J Haematol | 2026 | 42490742 | PubTator, text mining | PubMed |
1 to 10 of 3,351
See all 3,351 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1441
GET https://conductscience.org/api/genes/v1/1441/patents?page=2